Intelligent Trials: Diversity in Clinical Trials

White Paper

Intelligent Trials: Diversity in Clinical Trials

By Medidata

Intelligent Trials: Diversity in Clinical Trials

By Medidata

Enter your details to receive the free white paper:

By downloading this whitepaper, you acknowledge that New Statesman Media Group may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how New Statesman Media Group may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Diversity in clinical trials has been a long-standing issue across clinical research. Studies have historically failed to represent the patient population, with the majority of patients enrolled in trials being White, younger men. This has caused not only gaps in the industry’s understanding of how treatments in certain disease areas broadly affect diverse populations, but also inequitable access to treatments. As a result, lack of representation can also impede healthcare decision-making and future clinical development.

Download to find out more.

Intelligent Trials: Diversity in Clinical Trials

Intelligent Trials: Diversity in Clinical Trials

Changelog